Oxurion Announces New Strategic Orientation to De-risk and Diversify
Leuven, BELGIUM, 22 January 2024 9:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announced today its new corporate strategy to further diversify its activities by actively considering M&A opportunities, specifically in the healthcare sector.
Pascal Ghoson, CEO of Oxurion, states, “Oxurion today lays out its new corporate strategy, which is designed to further diversify and de-risk its ongoing activities. Starting March 2024, with a dedicated team of ten, we will proactively seek M&A opportunities, with a focus on healthcare companies to leverage the team’s expertise. This approach is not just about growth; it’s about enhancing our market presence with a robust business plan.”
Enhanced Funding Strategy
Atlas is currently the main funding partner of Oxurion, which has invested in the company by means of convertible bonds. “In the future we aim to use equity and debt funding to address our M&A targets. We are considering M&A transactions in the healthcare industry, where we can create the most added value with the current team. Our M&A pursuits will primarily target the healthcare industry in France and the Benelux region. We are interested in revenue-generating, mature businesses that promise lower risk and high potential,” Pascal Ghoson adds.
Commitment to Euronext Listing and Shareholder Engagement
The company is firmly committed to maintaining its listing on Euronext. "We have no intention of delisting from Euronext. Our evolving strategy is likely to attract significant investor interest.
We are reaching out to our existing and new shareholders to become part of this new exciting story and are looking for long-term investors. Our prime objective is to identify the targets, either on a case- by-case basis, or as a combination of smaller targets to create synergies and added value for our shareholders. Valuations have come down compared to a couple of years ago and this provides us with more acquisition opportunities.”
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is headquartered in Leuven, Belgium. More information is available at
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Oxurion NV
Pascal Ghoson, Chief Executive Officer
Attachments
